4.7 Article

Feasibility of NIH consensus criteria for chronic graft-versus-host disease

Journal

LEUKEMIA
Volume 23, Issue 1, Pages 78-84

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/leu.2008.276

Keywords

chronic graft-versus-host disease; NIH consensus criteria; revised Seattle criteria; GVHD-specific survival; discontinuation of immunosuppressive therapy

Ask authors/readers for more resources

To assess the applicability of the National Institutes of Health (NIH) consensus criteria (NCC) for chronic graft-versus-host disease (cGVHD), 211 patients who developed GVHD more than 100 days after allogeneic transplantation were reclassified using NCC. Classifications were: late acute GVHD (44 patients, 21%), overlap syndrome (64 patients, 30%) and classic cGVHD (103 patients, 49%). Classic cGVHD and overlap syndrome patients (n = 167) were graded using both the revised Seattle criteria (RSC) and NIH global scoring (NGS). Twenty-three patients (14%) had mild, 81 (48%) had moderate and 63 (38%) had severe cGVHD. After a median follow-up of 46 months (range 5-71 months), the 4- year GVHD-specific survival was not significantly different among the different subtypes of NCC. Among patients with late acute GVHD, however, the pattern of acute GVHD onset (late, persistent or recurrent) was significantly different with respect to GVHD-specific survival. Among patients with overlap syndrome and classic cGVHD, multivariate analysis showed that NGS as well as RSC were useful in predicting survival and discontinuation of immunosuppressive therapy despite of more detailed grouping. Our study indicates that NCC is applicable. The clinical impact of NIH types and NGS should be verified through prospective studies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Oncology

Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas

Jae-Ho Yoon, Young-Woo Jeon, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Hee-Je Kim, Chang-Ki Min, Jong-Wook Lee, Woo-Sung Min, Seok-Goo Cho

HEMATOLOGICAL ONCOLOGY (2017)

Article Hematology

Overcoming immunoregulatory plasticity of mesenchymal stem cells for accelerated clinical applications

Nayoun Kim, Seok-Goo Cho

INTERNATIONAL JOURNAL OF HEMATOLOGY (2016)

Article Hematology

Negative Impact of Unidirectional Host-versus-Graft Killer Cell Immunoglobulin-like Receptor Ligand Mismatch on Transplantation Outcomes after Unmanipulated Haploidentical Peripheral Blood Stem Cell Transplantation for Acute Myeloid Leukemia

Seung-Ah Yahng, Young-Woo Jeon, Jae-Ho Yoon, Seung-Hwan Shin, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong-Wook Lee, Woo-Sung Min, Hee-Je Kim

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)

Article Hematology

Infusions of Epstein-Barr virus-specific cytotoxic T lymphocytes as post-remission therapy in high-risk post-transplant lymphoproliferative disorder patients: report of two cases

Nayoun Kim, Hyun-Jung Sohn, Joo Hyun Oh, Young-Woo Jeon, Hyun-Joo Lee, Hyun-Il Cho, Byung Ha Chung, Chul-Woo Yang, Tai-Gyu Kim, Seok-Goo Cho

INTERNATIONAL JOURNAL OF HEMATOLOGY (2018)

Article Biophysics

A phase IV, randomized, multicenter, open-label trial comparing efficacy and systemic exposure for a standard weight-based dose versus a fixed dose of plerixafor in combination with G-CSF in patients with Non-Hodgkin's lymphoma weighing ≤70 kg

John Kuruvilla, Cheng-Hwai Tzeng, Seok-Goo Cho, Seok Jin Kim, Jih-Luh Tang, Yaming Su, Jingyang Wu, Rita Vargo, Peter Cheverton

BONE MARROW TRANSPLANTATION (2019)

Article Hematology

Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP

Young-Woo Jeon, Joo-Hyun O, Kyung-Sin Park, Gi June Min, Sung-Soo Park, Jae-Ho Yoon, Ki-Seong Eom, Chang-Ki Min, Seok-Goo Cho

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Article Biophysics

Incidence and risk factors of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in adults with prophylactic ursodiol and intravenous heparin or prostaglandin E1

Jae-Ho Yoon, Gi June Min, Sung-Soo Park, Silvia Park, Sung-Eun Lee, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Jong Wook Lee, Hee-Je Kim, Seok Lee

Summary: This study identified the incidence and survival outcome of hepatic sinusoidal obstruction syndrome/veno-occlusive disease (VOD/SOS) after hematopoietic cell transplantation (HCT) under a strategy of prophylactic ursodiol and intravenous heparin or prostaglandin E1. The overall incidence of hepatic VOD/SOS was 3.4% after allogeneic-HCT, with varying survival rates based on severity grades. Factors affecting development of VOD/SOS included disease risk index, gender, donor type, and busulfex dosage. Allogeneic-HCT using ursodiol and intravenous prophylaxis was considered safe, but early intervention for high-risk VOD/SOS patients is crucial.

BONE MARROW TRANSPLANTATION (2021)

Article Oncology

Relapse in patients with limited-stage ocular adnexal lymphoma treated by chemoimmunotherapy: Extended follow-up of a phase 2 study

Sung-Yong Kim, Won-Sik Lee, Sung Yong Oh, Deok-Hwan Yang, Hyo Jung Kim, Seong Kyu Park, Jae Wook Yang, Suk-Woo Yang, Seok-Goo Cho

Summary: In this study, the long-term efficacy of rituximab, cyclophosphamide, doxorubicin, and prednisolone (R-CVP) chemoimmunotherapy in limited-stage ocular adnexal mucosa-associated lymphoid tissue lymphoma (OAML) patients was investigated. The results showed a high response rate and a significant risk of late relapse. The study suggests that clinical trials for limited-stage OAML patients should have a long-term observation period and consider sequential or combination treatment to reduce the risk of delayed relapse.

CANCER MEDICINE (2022)

Article Hematology

A case of hemophagocytic lymphohistiocytosis following second dose of COVID-19 vaccination

Hee Won Park, Gi June Min, Tong Yoon Kim, Seok-Goo Cho

Summary: This case report describes a 21-year-old man who developed secondary HLH following the second dose of the BNT162b2 vaccine. He was treated with steroid pulse therapy without any other complications.

ACTA HAEMATOLOGICA (2022)

Article Oncology

Diagnosis, treatment, and prognosis of primary intraocular lymphoma: Single-center real-world clinical experience

Gi-June Min, Tong Yoon Kim, Young-Woo Jeon, Joo O. Hyun, Byung-Ock Choi, Gyeongsin Park, Young-Hoon Park, Seok-Goo Cho

Summary: This study aimed to identify factors indicative of PIOL, describe treatment outcomes, and determine modalities to prevent relapse. The study found that ophthalmologic and central nervous system relapse were common in PIOL patients regardless of the treatment modalities. Therefore, diagnosis should be based on clinical signs and assisted by vitrectomy, cytologic, molecular, and cytokine studies.

CANCER MEDICINE (2023)

Article Hematology

Long-term clinical outcomes of gastric mucosa-associated lymphoid tissue lymphoma in real-world experience

Gi-June Min, Donghoon Kang, Han Hee Lee, Seung-Jun Kim, Tong Yoon Kim, Young-Woo Jeon, Joo Hyun, Byung-Ock Choi, Gyeongsin Park, Seok-Goo Cho

Summary: This study evaluated the real-world clinical outcomes of different therapeutic modalities for gastric MALT lymphoma and analyzed factors affecting survival outcomes. Helicobacter pylori eradication was found to be effective in achieving complete remission in localized HPI-positive patients. Poor response to eradication was associated with lesions in specific locations and invasion depth, while HPI negativity correlated with poor progression-free survival. HPI eradication should be the first-line treatment for localized HPI-positive gastric MALT lymphoma, while radiotherapy is recommended for HPI-negative patients or when eradication fails.

ANNALS OF HEMATOLOGY (2023)

Article Multidisciplinary Sciences

Changes in choroidal vascular structure from vitreoretinal lymphoma and the intraocular cytokine level associated with clinical resolution after intravitreal methotrexate treatment

Rae-Young Kim, Jae Hyun Park, Mirinae Kim, Young-Geun Park, Seok-Goo Cho, Young-Hoon Park

Summary: The study evaluated changes in choroidal vascular structure and aqueous cytokine levels in eyes with vitreoretinal lymphoma (VRL) after treatment with intravitreal methotrexate (MTX). Results showed improvements in choroidal structure and cytokine levels after treatment, indicating potential factors influencing treatment outcomes for VRL patients.

PLOS ONE (2021)

Letter Hematology

Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab

Frits van Rhee, Jean-Francois Rossi, David Simpson, Alexander Fossa, Angela Dispenzieri, John Kuruvilla, Yeow Tee Goh, Seok-Goo Cho, Marcelo Capra, Ting Liu, Corey Casper, James Cavet, Raymond S. Wong

BRITISH JOURNAL OF HAEMATOLOGY (2021)

Article Medicine, General & Internal

Comparison of Selection and Long-term Clinical Outcomes Between Chemotherapy and Radiotherapy as Primary Therapeutic Modality for Ocular Adnexal MALT Lymphoma

Young-Woo Jeon, Hee-Jung Yang, Byung-Ock Choi, Seung-Eun Jung, Kyung-Sin Park, O. Joo-Hyun, Suk-Woo Yang, Seok-Goo Cho

ECLINICALMEDICINE (2018)

No Data Available